Adherence and quality of life in adults and children during 3-years of SLIT treatment with Grazax-a real life study
(2018) In npj Primary Care Respiratory Medicine 28(1).- Abstract
Respiratory allergic disease represents a global health problem, 30% of the population suffers from allergic rhinoconjunctivitis and 20% suffer from asthma. Allergy immunotherapy induce immunological tolerance and thereby modify the response to allergens and sublingual immunotherapy (SLIT) offers the possibility of home administration of allergen therapy, but adherence is more uncertain. The aim of the study was to investigate the adherence with GRAZAX in adults and children ≥ 5 years during three consecutive years of treatment. This was a non-interventional, prospective, observational, multi-center, open-label study to investigate adherence, quality of life, safety and tolerability of GRAZAX in adult and pediatric patients in a... (More)
Respiratory allergic disease represents a global health problem, 30% of the population suffers from allergic rhinoconjunctivitis and 20% suffer from asthma. Allergy immunotherapy induce immunological tolerance and thereby modify the response to allergens and sublingual immunotherapy (SLIT) offers the possibility of home administration of allergen therapy, but adherence is more uncertain. The aim of the study was to investigate the adherence with GRAZAX in adults and children ≥ 5 years during three consecutive years of treatment. This was a non-interventional, prospective, observational, multi-center, open-label study to investigate adherence, quality of life, safety and tolerability of GRAZAX in adult and pediatric patients in a real-life setting. During the 3-years study period estimation of adherence was done regularly. Quality of life as well as symptom score was also assessed. In total, 399 patients (236 adults and 163 children) were included in the study. At baseline, 100% suffered from moderate-severe eyes and nose symptoms, and 31% had asthma in the grass pollen season. Overall, 55% completed a 3-years treatment period, whereas 37% stopped before end of study and 8% were lost to follow up. After 3 years, the adherence rate decreased from 98.2% (first month), 93.7% (first year), 93.2% (second year) and 88.9% (third year) and adverse events were the main reason for pre-term termination. The study suggests a good adherence to treatment in a real life setting among the patients finalizing 3-years SLIT therapy. The treatment was effective both on symptoms and HRQL.
(Less)
- author
- Kiotseridis, Hampus LU ; Arvidsson, Peter ; Backer, Vibeke ; Braendholt, Vagn and Tunsäter, Alf LU
- organization
- publishing date
- 2018-02-12
- type
- Contribution to journal
- publication status
- published
- subject
- in
- npj Primary Care Respiratory Medicine
- volume
- 28
- issue
- 1
- article number
- 4
- publisher
- Nature Publishing Group
- external identifiers
-
- scopus:85041949973
- pmid:29434271
- ISSN
- 2055-1010
- DOI
- 10.1038/s41533-018-0072-z
- language
- English
- LU publication?
- yes
- id
- 4f23e63b-15f9-433f-bc24-f68fe6be5397
- date added to LUP
- 2018-02-20 11:35:50
- date last changed
- 2024-06-11 10:49:22
@article{4f23e63b-15f9-433f-bc24-f68fe6be5397,
abstract = {{<p>Respiratory allergic disease represents a global health problem, 30% of the population suffers from allergic rhinoconjunctivitis and 20% suffer from asthma. Allergy immunotherapy induce immunological tolerance and thereby modify the response to allergens and sublingual immunotherapy (SLIT) offers the possibility of home administration of allergen therapy, but adherence is more uncertain. The aim of the study was to investigate the adherence with GRAZAX in adults and children ≥ 5 years during three consecutive years of treatment. This was a non-interventional, prospective, observational, multi-center, open-label study to investigate adherence, quality of life, safety and tolerability of GRAZAX in adult and pediatric patients in a real-life setting. During the 3-years study period estimation of adherence was done regularly. Quality of life as well as symptom score was also assessed. In total, 399 patients (236 adults and 163 children) were included in the study. At baseline, 100% suffered from moderate-severe eyes and nose symptoms, and 31% had asthma in the grass pollen season. Overall, 55% completed a 3-years treatment period, whereas 37% stopped before end of study and 8% were lost to follow up. After 3 years, the adherence rate decreased from 98.2% (first month), 93.7% (first year), 93.2% (second year) and 88.9% (third year) and adverse events were the main reason for pre-term termination. The study suggests a good adherence to treatment in a real life setting among the patients finalizing 3-years SLIT therapy. The treatment was effective both on symptoms and HRQL.</p>}},
author = {{Kiotseridis, Hampus and Arvidsson, Peter and Backer, Vibeke and Braendholt, Vagn and Tunsäter, Alf}},
issn = {{2055-1010}},
language = {{eng}},
month = {{02}},
number = {{1}},
publisher = {{Nature Publishing Group}},
series = {{npj Primary Care Respiratory Medicine}},
title = {{Adherence and quality of life in adults and children during 3-years of SLIT treatment with Grazax-a real life study}},
url = {{http://dx.doi.org/10.1038/s41533-018-0072-z}},
doi = {{10.1038/s41533-018-0072-z}},
volume = {{28}},
year = {{2018}},
}